Compare MOMO & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOMO | SGP |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 932.9M |
| IPO Year | 2014 | N/A |
| Metric | MOMO | SGP |
|---|---|---|
| Price | $5.89 | $20.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 753.8K | 96.9K |
| Earning Date | 03-18-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.65 | N/A |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $20.15 |
| 52 Week High | $9.22 | $30.56 |
| Indicator | MOMO | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 36.52 |
| Support Level | $5.69 | $20.72 |
| Resistance Level | $7.14 | $28.17 |
| Average True Range (ATR) | 0.13 | 2.17 |
| MACD | 0.04 | -0.35 |
| Stochastic Oscillator | 31.50 | 10.18 |
Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines, out of which Momo's service lines segment derives the majority of revenue.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.